Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 57 articles: HTML format

Single Articles

June 2026
1. SHARIFI N
   Fasting, Glucocorticoids, and Breast Cancer.
   N Engl J Med. 2026;394:2163-2165.
   PubMed    
   
   
   April 2026
2. METZGER O
   Palbociclib for HR-Positive, HER2-Positive Breast Cancer. Reply.
   N Engl J Med. 2026;394:1765-1766.
   PubMed    
   
   
   
3. LI F, Zhang L
   Palbociclib for HR-Positive, HER2-Positive Breast Cancer.
   N Engl J Med. 2026;394:1764-1765.
   PubMed    
   
   
   
4. JING S, Song J
   Palbociclib for HR-Positive, HER2-Positive Breast Cancer.
   N Engl J Med. 2026;394:1764.
   PubMed    
   
   
   
5. TOLANEY SM, Schmid P
   Sacituzumab Govitecan for Triple-Negative Breast Cancer. Reply.
   N Engl J Med. 2026;394:1554.
   PubMed    
   
   
   
6. XIAO L, Lin C
   Sacituzumab Govitecan for Triple-Negative Breast Cancer.
   N Engl J Med. 2026;394:1553.
   PubMed    
   
   
   
7. 
   Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
   N Engl J Med. 2026;394:1352.
   PubMed    
   
   
   February 2026
8. RUGO HS
   Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer.
   N Engl J Med. 2026;394:918-920.
   PubMed    
   
   
   
9. CORTES J, Tolaney SM
   Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer. Reply.
   N Engl J Med. 2026;394:620-621.
   PubMed    
   
   
   
10. OLIVIER T, Schnog JB
    Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2026;394:620.
    PubMed    
    
    
    January 2026
11. METZGER O, Mandrekar S, Goel S, Gligorov J, et al
    Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.
    N Engl J Med. 2026;394:451-462.
    PubMed     Abstract available
    
    
    
12. TOLANEY SM, de Azambuja E, Kalinsky K, Loi S, et al
    Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2026;394:354-366.
    PubMed     Abstract available
    
    
    December 2025
13. LOIBL S, Park YH, Shao Z, Huang CS, et al
    Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
    N Engl J Med. 2025 Dec 10. doi: 10.1056/NEJMoa2514661.
    PubMed     Abstract available
    
    
    November 2025
14. CAMPONE M
    Vepdegestrant in Advanced Breast Cancer. Reply.
    N Engl J Med. 2025;393:1862.
    PubMed    
    
    
    
15. SHIMOI T, Yonemori K
    Vepdegestrant in Advanced Breast Cancer.
    N Engl J Med. 2025;393:1862.
    PubMed    
    
    
    
16. TROVATO G, Tortora G
    Vepdegestrant in Advanced Breast Cancer.
    N Engl J Med. 2025;393:1861.
    PubMed    
    
    
    
17. DE BONIFACE J
    Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer.
    N Engl J Med. 2025;393:1852-1853.
    PubMed    
    
    
    
18. KUNKLER IH, Russell NS, Anderson N, Sainsbury R, et al
    Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.
    N Engl J Med. 2025;393:1771-1783.
    PubMed     Abstract available
    
    
    October 2025
19. TOLANEY SM, Jiang Z, Zhang Q, Barroso-Sousa R, et al
    Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
    N Engl J Med. 2025 Oct 29. doi: 10.1056/NEJMoa2508668.
    PubMed     Abstract available
    
    
    
20. CORTES J, Punie K, Barrios C, Hurvitz SA, et al
    Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2025 Oct 19. doi: 10.1056/NEJMoa2511734.
    PubMed     Abstract available
    
    
    August 2025
21. MCDONNELL DP
    Degradation of the Estrogen Receptor in Breast Cancer.
    N Engl J Med. 2025;393:604-608.
    PubMed    
    
    
    June 2025
22. MAMOUNAS EP, Bandos H, White JR, Julian TB, et al
    Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
    N Engl J Med. 2025;392:2113-2124.
    PubMed     Abstract available
    
    
    
23. PARTRIDGE AH
    Menopausal Symptom Management in Breast Cancer Survivors - A Promising New Option.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMe2506475.
    PubMed    
    
    
    
24. CARDOSO F, Parke S, Brennan DJ, Briggs P, et al
    Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2415566.
    PubMed     Abstract available
    
    
    
25. BIDARD FC, Mayer EL, Park YH, Janni W, et al
    First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
    N Engl J Med. 2025 Jun 1. doi: 10.1056/NEJMoa2502929.
    PubMed     Abstract available
    
    
    May 2025
26. CAMPONE M, De Laurentiis M, Jhaveri K, Hu X, et al
    Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
    N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2505725.
    PubMed     Abstract available
    
    
    
27. JHAVERI KL, Im SA, Saura C, Loibl S, et al
    Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
    N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2501796.
    PubMed     Abstract available
    
    
    March 2025
28. SCHMID P, Zhou X, Dent R
    Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2025;392:1142.
    PubMed    
    
    
    
29. SORSCHER S
    Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2025;392:1141-1142.
    PubMed    
    
    
    
30. SUN R, Seibert TM, Wei LJ
    Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2025;392:1141.
    PubMed    
    
    
    
31. NEVEN P, Floris G, Desmedt C
    Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2025;392:1140-1141.
    PubMed    
    
    
    February 2025
32. BARDIA A, Schwaederle M, Curigliano G
    Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply.
    N Engl J Med. 2025;392:830-831.
    PubMed    
    
    
    
33. CONFORTI F, Oriecuia C, Pala L
    Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
    N Engl J Med. 2025;392:830.
    PubMed    
    
    
    
34. HUANG R, Chen M, Shi Y
    Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
    N Engl J Med. 2025;392:829-830.
    PubMed    
    
    
    
35. WOLFF AC, McShane LM, Allison KH
    Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
    N Engl J Med. 2025;392:829.
    PubMed    
    
    
    January 2025
36. TURNER NC, Thanopoulou E, Jhaveri KL
    Inavolisib Therapy in Advanced Breast Cancer. Reply.
    N Engl J Med. 2025;392:310-311.
    PubMed    
    
    
    
37. IBRAHEEM AF, Nguyen R, Gadi VK
    Inavolisib Therapy in Advanced Breast Cancer.
    N Engl J Med. 2025;392:310.
    PubMed    
    
    
    
38. GEYER CE JR, Untch M, Huang CS, Mano MS, et al
    Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
    N Engl J Med. 2025;392:249-257.
    PubMed     Abstract available
    
    
    December 2024
39. MORROW M
    Sentinel-Lymph-Node Biopsy in Early-Stage Breast Cancer - Is It Obsolete?
    N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMe2414899.
    PubMed    
    
    
    
40. REIMER T, Stachs A, Veselinovic K, Kuhn T, et al
    Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.
    N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMoa2412063.
    PubMed     Abstract available
    
    
    
41. JHAVERI KL, Neven P, Casalnuovo ML, Kim SB, et al
    Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
    N Engl J Med. 2024 Dec 11. doi: 10.1056/NEJMoa2410858.
    PubMed     Abstract available
    
    
    November 2024
42. BURSTEIN HJ
    Immunotherapy for Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2024;391:2048-2049.
    PubMed    
    
    
    October 2024
43. GRADISHAR WJ
    Improving the Outcome of Bad-Acting Hormone Receptor-Positive Breast Cancer.
    N Engl J Med. 2024;391:1644-1647.
    PubMed    
    
    
    
44. TURNER NC, Im SA, Saura C, Juric D, et al
    Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.
    N Engl J Med. 2024;391:1584-1596.
    PubMed     Abstract available
    
    
    September 2024
45. RUBIN EJ, Yeku OO, Morrissey S
    NEJM at ESMO - Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMe2411492.
    PubMed    
    
    
    
46. RUBIN EJ, Yeku OO, Morrissey S
    NEJM at ESMO - Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMe2411488.
    PubMed    
    
    
    
47. SCHMID P, Cortes J, Dent R, McArthur H, et al
    Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2409932.
    PubMed     Abstract available
    
    
    
48. BARDIA A, Hu X, Dent R, Yonemori K, et al
    Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2407086.
    PubMed     Abstract available
    
    
    August 2024
49. WANDER SA, Thai JN, Wirth LJ, Soto DE, et al
    Case 26-2024: A 59-Year-Old Woman with Aphasia, Anemia, and a Breast Mass.
    N Engl J Med. 2024;391:747-757.
    PubMed    
    
    
    June 2024
50. SLAMON D, Yardley DA, Hortobagyi G
    Ribociclib plus Endocrine Therapy in Early Breast Cancer. Reply.
    N Engl J Med. 2024;390:2221-2222.
    PubMed    
    
    
    
51. TANNOCK IF, Meirson T, Fojo A
    Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    N Engl J Med. 2024;390:2220-2221.
    PubMed    
    
    
    
52. LI Q, Cai Y, Li J
    Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    N Engl J Med. 2024;390:2220.
    PubMed    
    
    
    
53. TU H, Zhang Y, You Z
    Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    N Engl J Med. 2024;390:2219-2220.
    PubMed    
    
    
    
54. VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al
    Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
    N Engl J Med. 2024;390:2011-2022.
    PubMed    
    
    
    April 2024
55. DE BONIFACE J, Filtenborg Tvedskov T, Ryden L, Szulkin R, et al
    Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
    N Engl J Med. 2024;390:1163-1175.
    PubMed     Abstract available
    
    
    
56. MCGUIRE KP
    Axillary Dissection - The Bell Tolls for Thee.
    N Engl J Med. 2024;390:1231-1232.
    PubMed    
    
    
    March 2024
57. SLAMON D, Lipatov O, Nowecki Z, McAndrew N, et al
    Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    N Engl J Med. 2024;390:1080-1091.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum